The new medicare drug benefit: formularies and their potential effects on access to medications.
- 1 July 2005
- journal article
- Published by Emerald
- Vol. 20 (7), 662-5
- https://doi.org/10.1111/j.1525-1497.2005.0110.x
Abstract
During congressional debate over the Medicare Part D prescription drug benefit, much attention was focused on nominal benefit design. Relatively little attention was paid to details about how plans would operate, such as the design of drug formularies. Yet, formularies will be important tools for controlling costs, and may be as important as nominal benefit design in determining enrollees' access to medications and out-of-pocket costs. We describe Part D plan incentives and how they may influence formulary design, and then provide recommendations for Part D formulary implementation. We encourage the Centers for Medicare & Medicaid Services (CMS) to develop standardized tools to provide physicians and patients with up-to-date and easily accessible information about covered drugs on each plan's formulary (perhaps via a central website) and a national set of easy-to-follow procedures for reconsideration and appeals. Such efforts should reduce administrative burden and better allow physicians to help patients obtain needed medications.This publication has 13 references indexed in Scilit:
- Predicting pharmacy costs and other medical costs using diagnoses and drug claims.2005
- Barriers to patient-physician communication about out-of-pocket costsJournal of General Internal Medicine, 2004
- Pharmacy Benefits and the Use of Drugs by the Chronically IllJAMA, 2004
- Provider Perceptions of Pharmacy ManagementMedical Care, 2004
- Physicians’ Views Of Formularies: Implications For Medicare Drug Benefit DesignHealth Affairs, 2004
- The Effect of Incentive-Based Formularies on Prescription-Drug Utilization and SpendingThe New England Journal of Medicine, 2003
- Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockersClinical Pharmacology & Therapeutics, 2003
- Outcomes of Reference Pricing for Angiotensin-Converting–Enzyme InhibitorsThe New England Journal of Medicine, 2002
- Physician perceptions of a national formulary.2001
- The effect of prior-year health expenditures on health coverage plan choice.1985